MedTrace Logo

Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC

NCT00908752 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 734

Last updated 2019-12-02

No results posted yet for this study

Summary

The purpose of this study is to compare the Overall Survival (OS) of HCC patients who receive brivanib as adjuvant treatments to TACE therapy, with the OS of HCC patients who receive matched placebo with TACE therapy.

Conditions

Interventions

DRUG

Brivanib

Tablets, Oral, 200 mg, once daily, until disease progression or toxicity

OTHER

Brivanib Placebo

Tablets, Oral, 0 mg, once daily, until disease progression or toxicity

PROCEDURE

TACE Therapy

Trans-Arterial Chemo-Embolization Therapy

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-20
Primary Completion
2012-09-28
Completion
2018-01-26

Countries

  • United States
  • Argentina
  • Australia
  • Canada
  • China
  • France
  • Hong Kong
  • Italy
  • Japan
  • South Korea
  • Spain
  • Taiwan
  • Thailand

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00908752 on ClinicalTrials.gov